BNTX250117P160000
- 63.23
- 0.000.00%
BioNTech Newsroom
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
4 Stocks to Watch on Friday: NFLX, AAPL on $4T Watch and More
BioNTech Settles Lawsuits With US NIH, UPenn Over Covid Vaccine Royalties
BioNTech Settles Royalty Dispute With NIH for $791.5 Million
Express News | BioNTech Entered Settlement Agreement With NIH for $791.5M Over COVID-19 Vaccine Royalties (2020-2023)
Express News | BioNTech SE: Under Terms, Co, Penn Would Enter Settlement Agreement, for Which Co Would, Among Other Things, Pay up to $467.0 Mln to Penn
BioNTech SE ADR Rises Tuesday, Still Underperforms Market
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND)
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $154.43
BioNTech SE's Strategic and Clinical Advancements Drive Buy Rating on BNT327's Promise in Oncology
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Announces Target Price $122
J.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
FDA Lifts Hold on BioNTech's Key Cancer Trial
BioNTech Says Partial Clinical Hold on BNT316 Study Lifted
Express News | Evonik Industries - to Organize Its Business Lines in Two New Segments: Custom Solutions and Advanced Technologies
Express News | Evonik Industries - to Reduce Number of Management Levels From Average of Ten to Maximum of Six by End of 2026
Express News | Evonik Industries - Both Segments Currently Have Annual Sales of Around EUR 6 Bln Each
Express News | Evonik Industries CEO: 2024 Is a Good Year for Evonik